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Abstract. Alzheimer’s disease (AD) is the leading cause of cognitive impairment in the elderly. Recent evidence suggests
that preventive interventional trials could significantly reduce the risk for development of dementia. Periodontitis is the
most common dental disease characterized by chronic inflammation and loss of alveolar bone and perialveolar attachment
of teeth. Growing number of studies propose a potential link between periodontitis and neurodegeneration. In the first part
of the paper, we overview case-control studies analyzing the prevalence of periodontitis among AD patients and healthy
controls. Second, we survey observational libraries and cross-sectional studies investigating the risk of cognitive decline
in patients with periodontitis. Next, we describe the current view on the mechanism of periodontitis linked neural damage,
highlighting bacterial invasion of neural tissue from dental plaques, and periodontitis induced systemic inflammation resulting
in a neuroinflammatory process. Later, we summarize reports connecting the four most common periodontal pathogens to
AD pathology. Finally, we provide a practical guide for further prevalence and interventional studies on the management of
cognitively high-risk patients with and without periodontitis. In this section, we highlight strategies for risk control, patient
information, dental evaluation, reporting protocol and dental procedures in the clinical management of patients with a risk
for periodontitis and with diagnosed periodontitis. In conclusion, our review summarizes the current view on the association
between AD and periodontitis and provides a research and intervention strategy for harmonized interventional trials and for
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Alzheimer’s disease (AD) is the leading cause of 30
cognitive decline affecting millions of people world- 31
wide [1]. Symptoms usually occur at in the 60s and 32
70s of patients, starting with the loss of episodic mem- 33
ory functions, impairment of visuo-spatial skills, and 34
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orientation difficulties. AD is characterized by the35
pathologic accumulation of hyperphosphorylated tau36
neurofibrils and amyloid plaques in the neural tis-37
sue leading to progressive neurodegeneration [2].38
Histology and molecular studies revealed that the39
pathologic process starts with the formation of extra-40
cellular amyloid deposits, and it leads to changes41
in the production, phosphorylation, cleavage, and42
elimination of tau. The proposed phenomenon is43
known as the amyloid cascade theory [3]. A rel-44
atively novel idea that the early changes in the45
misfolding process of pathologic proteins are highly46
influenced by inflammatory mechanisms shifting the47
anti-inflammatory processes into a pro-inflammatory48
state. It is defined as the inflammatory hypothesis of49
AD [4]. Seemingly, only 1–3% of AD cases are char-50
acterized by the mutation of a single gene typically51
leading to prominent changes of amyloid metabolism52
and resulting in the familial forms of AD [5]. In most53
patients, genetic risk and environmental factors both54
contribute to the pathologic process.55
While the deterioration of cognitive abilities56
is currently not treatable, growing body of evi-57
dence proposes the beneficial effect of personalized58
interventional therapy on the prevention of AD.59
A 2-year Finnish multidomain interventional trial60
applying diet changes, regular exercise, cognitive61
training, and monitoring of cardiovascular risk fac-62
tors demonstrated that personalized intervention63
can significantly improve or maintain the cogni-64
tive functions of elderly individuals [6]. This has65
been reinforced by a meta-analysis of population-66
based European and American studies founding that67
approximately 30% of AD cases is caused by modifi-68
able conditions including diabetes, midlife obesity,69
midlife hypertension, depression, smoking, physi-70
cal inactivity, and low educational background [7].71
Additional but less known factors might be impor-72
tant contributors as well such as kidney disease [8],73
hearing loss [9], sleep apnea [10], anxiety [11], early74
menopause [12], and epileptic seizures and epilepti-75
form activity [13]. Oral diseases might be potential76
candidates due to the high population prevalence and77
the interaction with inflammatory mediators [14].78
Periodontal disease or periodontitis (PD) is the79
most common oral condition affecting approximately80
20–50% of human population [15]. PD is a chronic81
inflammatory disease of the periodontium resulting82
in loss of perialveolar ligaments and alveolar bony83
material. This process is primary related to the accu-84
mulation of pathogenic bacteria in subgingival dental85
plaques [16]. The continuous inflammation results86
in apical migration of the gingival junction forming 87
periodontal pockets serving as continuous reservoir 88
for the pathogenic bacteria. PD progresses slowly and 89
long-term outcome depends on the speed of bacterial 90
accumulation of the dental plaques [15]. Untreated 91
PD may lead to chronic inflammation and increased 92
tooth mobility [17]. The risk factors of PD are shared 93
with AD in a large extent including aging, smok- 94
ing, female hormonal changes, diabetes, obesity, and 95
chronic stress [1, 15]. While it can easily lead to 96
tooth loss and therefore significantly affecting the 97
quality of life, it also associates with numerous phys- 98
ical conditions. A meta-analysis of 9 studies found 99
that PD increases the risk of cardiovascular disease 100
with 19% and the elevation is more prominent at the 101
age > 65 reaching 44% relative risk [18]. A prospec- 102
tive cohort study analyzing 628 subjects identified 103
that diabetic patients with severe PD have 3.2-times 104
elevated mortality in a 11-year follow-up [19]. Obser- 105
vational studies also found that PD patients have 106
a significantly higher risk for developing chronic 107
kidney disease [20], respiratory diseases [21], and 108
gastrointestinal cancers [22]. Since AD and PD share 109
many risk factors and they associate with similar 110
chronic physical conditions, it is intriguing to ana- 111
lyze their potential connection in the pathophysiology 112
of AD. 113
The aim of the current opinion review is to sum- 114
marize the results of studies on the prevalence of 115
cognitive decline among patients with oral diseases 116
and prevalence of PD in AD patients. Furthermore, 117
we also highlight the possible pathologic mecha- 118
nisms linking PD and AD with the description of 119
the potential bacterial candidates. We also propose 120
exact promising therapeutic approaches with a prac- 121
tical guide, potentially serving as a basis for further 122
interventional studies. 123
PREVALENCE OF ORAL DISEASES IN 124
ALZHEIMER’S DISEASE 125
Patients with cognitive decline have a higher 126
chance for impaired physical condition since neu- 127
rodegenerative diseases like AD significantly affect 128
self-care, motor, and autonomic functions. This 129
leaves us with patients who are either unable or 130
uninterested in carrying out daily hygienic tasks 131
and in addition, some pharmacological treatment 132
given to AD patients decrease salivary flow and 133
increase risk of dental caries as well as xerosoto- 134
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existing literature, we searched studies identifying136
periodontal (or unhealthy dental state in general) sta-137
tus in AD patients. A search for “Periodontitis” and138
“Alzheimer” in PubMed yielded 171 results (years139
2000–2020), and we selected papers for review based140
on the following inclusion criteria: 1) case-control141
studies with at least 40 subjects; 2) papers with142
meta-analysis method; 3) compared subject groups143
consist of healthy controls versus patients with AD144
spectrum disease (AD or amnestic type mild cog-145
nitive impairment (MCI)); 4) original peer-reviewed146
articles published in academic journals with impact147
factors. Cohort or cross-sectional studies were not148
included. We preferred the case-control design since149
databases on AD patients and healthy controls con-150
taining dental records are barely available. 13 studies151
(10 case-control and 3 meta-analysis) met the pro-152
posed criteria.153
A case-control study [24] including 70 AD patients154
and 36 healthy controls reported that tooth loss in155
the AD group was 2.5-times more frequent than in156
the control group, and AD patients had 3 times more157
filled teeth and dental caries than the control group.158
It was found that the age and presence of AD were159
strong predictive factors for diminished condition of160
oral health. Poor periodontal health was also observed161
in the AD group compared to healthy controls [24].162
Another study [25] investigated the oral health of 154163
patients with neurocognitive decline (ranging from164
MCI to AD) and concluded that PD was associated165
with early cognitive impairment and AD, highlight-166
ing the increased number of deep periodontal pockets167
(OR = 8.43) and dental caries (OR = 3.36) in the neu-168
rodegenerative cases compared to controls [25].169
A handful of systematic meta-analysis papers have170
recently been published to help determine whether171
the available evidence supports the higher incidence172
of PD in dementia [26–29]. A study of Gusman et173
al. [27] analyzed 4 reports (3 case-control and 1174
cross-sectional) revealed significantly higher occur-175
rence of PD in dementia; however, with the removal176
of the cross-sectional report, results appeared non-177
significant. The report of Maldonado et al. included178
5 studies (3 case-controls and 2 cross-sectionals)179
and demonstrated that AD patients show significantly180
worse periodontal variables [28]. A recent paper from181
Asher et al. analyzed 16 studies and demonstrated182
that partial tooth loss was associated with high risk183
of cognitive impairment. It also states that the overall184
quality of evidence is low [29]. These reports agreed185
that most of the reviewed studies conducted only a186
point-analysis with various dental methodology, so it187
was impossible to rule out the deterministic role of 188
impaired dental status in cognitive impairment. They 189
also concluded that well designed, large sample size, 190
longitudinal studies were needed to confirm the corre- 191
lation between the development of AD and presence 192
of PD [30]. 193
In one such longitudinal study [31], the serum 194
IG levels of bacteria (recognized as PD pathogens) 195
were measured in 219 subjects. Although it is known 196
that the physiological antibody responses to peri- 197
odontal bacteria are influenced by many different 198
factors beyond the clinical periodontal status (such as 199
race/ethnicity, smoking habits, and likely also unmea- 200
sured health behaviors), the study found that patients 201
with cognitive decline had higher serum IgG levels 202
to common periodontal microbiota [31]. 203
All case-control studies (see Table 1) compared 204
cognitively impaired individuals to healthy controls 205
with group comparisons focusing on dental status 206
as dependent variable. All converge on a consensus 207
of declined periodontal health in patients with AD 208
spectrum disorders compared to their age matched 209
controls. The cited reports used mostly retrospec- 210
tive approach and did not analyze cognitively normal 211
patients with PD in a prospective follow-up. It should 212
be noted that all studies propose statements regarding 213
the need for further investigation, mainly prospective 214
longitudinal to reveal the role and importance of PD 215
in the progression of AD. 216
RISK OF COGNITIVE DECLINE IN 217
PATIENTS WITH ORAL DISEASES 218
Oral diseases like caries, PD, oral cancers, oro- 219
dental trauma, cleft lip and palate, and noma pose a 220
prominent health burden for all countries, affecting 221
approximately half of the human population [39]. 222
Oral diseases frequently associate to higher occur- 223
rence of many physical conditions [15] and seemingly 224
to neurological disorders as well. 225
To fully understand the causative direction of PD- 226
AD link, the frequency of cognitive decline in patients 227
with decreased oral health but normal cognitive sta- 228
tus must be investigated. If AD patients were found 229
to have a higher incidence of periodontal charac- 230
teristic (as it was shown in the previous section of 231
this paper), but we cannot find an increased rate 232
of cognitive decline among patients with known 233
oral diseases, we cannot attribute the inflammatory 234
component of PD to the neurocognitive decline. 235
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Table 1
Summary of case- control studies analyzing the presence of periodontitis in Alzheimer’s disease spectrum patients
Study Number of subjects Major findings
Aragón et al., 2018 [24] 70 AD, 36 Control Statistically significant worse dental, periodontal,
salivary, and prosthetic status among AD group
compared to control.
Holmer et al., 2018 [25] 154 AD, MCI, and SCD
cases, 69 Control
Alveolar bone loss and decreased oral health (deep
periodontal pockets and dental caries) was
statistically significant in the CI group.
Rolim et al., 2014 [32] 29 AD, 30 Control High prevalence of periodontal infections (p = 0.002) in
AD group compared to control.
Noble et al., 2014 [31] 110 AD, 109 Control Higher serum IgG levels against common PD bacteria in
AD.
Maurer et al., 2018 [33] 20 AD, 20 Control Higher bacterial load and inflammation levels was
shown in AD cases compared to controls. Antibiotic
treatment reduced periodontitis and improved
cognition in AD cases.
Lin et al., 2020 [34] 209112 AD, 836448
Control
Extraction of more than 4 teeth associates with higher
occurrence of dementia.
Cestari et al., 2016 [35] 25 AD, 19 MCI, 21
Control
AD patients have higher IL-6 serum level, while
patients with PD have higher TNF-alfa. There is an
overlap in the cytokine profile between PD and AD.
Rai et al., 2010 [36] 20 AD, 32 Control Higher level of cytokines in AD. Higher prevalence of
gingival inflammation, dental plaque, bleeding on
probing and larger probing pocket depth in AD.
Gatz et al., 2006 [37] 310 CI, 3063 Control Higher occurrence of teeth loss before age 35 in
dementia group.
Gil Montaya et al., 2015 [38] 180 CI, 229 Control Significant association between cognitive impairment
and clinical attachment loss.
AD, Alzheimer’s disease; MCI, mild cognitive impairment; SCD, subjective cognitive decline; PD, periodontitis; CRP, C-reactive protein;
IL-6, interleukin 6; MMSE, Mini-Mental State Examination; CI, cognitive impairment.
described results we selected studies using the fol-237
lowing criteria: 1) matched-cohort or cross-sectional238
observational studies with at least 40 subjects; 2)239
papers with meta-analysis method; 3) compared sub-240
ject groups consist of healthy controls versus patients241
with PD; 4) original peer-reviewed articles pub-242
lished in academic journals with impact factors.243
We preferred the matched-cohort or cross-sectional244
observational design since large databases contain-245
ing dental records are available on cognitively normal246
individuals. Twelve studies met the proposed criteria247
(see Table 2). Studies with meta-analysis were not248
available.249
Six studies applied retrospective approach. A250
nationwide population based matched-cohort study251
analyzing cognitive decline in patients with con-252
firmed dental diseases was conducted in Taiwan.253
This impressively large study [40] included 9,291254
patients aged 50 + who had been newly diagnosed255
with chronic PD. This sample was compared to256
18,672 patients without PD, matched according to257
sex, age, and index years (1:2 ratio). Both groups258
were followed from the index date until the diag-259
nosis of AD, death, or 31 December 2013. While260
the study found that there is no significant differ-261
ence between the groups regarding 1-year risk of 262
AD development after chronic PD exposure, 10-year 263
PD CP exposure was associated with a 1.707-fold 264
increase in the risk of developing AD [40]. The 265
Third National Health and Nutrition Examination 266
Survey (NHANES-III) containing medical data of 267
2,355 individuals revealed that high level of Por- 268
phyriomonas gingivalis (P. gingivalis) antibody was 269
significantly connected to lower performance on 270
delayed verbal memory (OR: 3.01) [41]. A second 271
analysis of the same cohort examined the relationship 272
between oral health indicators (gingival bleeding, 273
loss of periodontal attachment, loss of teeth) and 274
cognitive function (measured with Symbol Digit Sub- 275
stitution Test, Serial Digit Learning Test and Story 276
Recall test) among 5,138 participants. After covariate 277
adjustment, gingival bleeding and loss of periodon- 278
tal attachment was associated with impairment in 279
digit substitution performance and gingival bleeding 280
was connected to decreased ability of digit learning 281
[42]. An impressively robust report of the National 282
Health Insurance Service-National Health Screening 283
Retrospective Cohort database of South Korea ana- 284
lyzed 10,115 patients with chronic PD and 10,115 285
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Table 2
Summary of matched-cohort and cross-sectional observational studies analyzing the risk of cognitive decline in patients with oral diseases
Study Number of subjects Major findings
Chen et al., 2017 [40] 9,291 CP, 18,672 Control Subjects with CP had a higher risk of developing AD
than those without CP.
Noble et al., 2009 [41] 2,355 Subjects Higher levels of P. gingivalis IgG is associated with
poor delayed verbal recall and subtraction regardless
of socioeconomic and vascular variables.
Stewart et al., 2008 [42] 6,693 Subjects Worse scores on oral health status are linked to poorer
age-adjusted cognitive function.
Kim et al., 2020 [43] 10,115 PD, 10,115
Control
Patients with severe periodontitis with 1-9 remaining
teeth had a significantly higher risk of developing AD,
vascular dementia, and mixed dementia.
Han et al., 2020 [44] 411 Subjects Smaller number of functional teeth and functional
occlusal units is linked to increased cognitive
impairment.
Kamer et al., 2012 [45] 150 Subjects Participants with PI with higher number of missing teeth
have lower mean scores on the Digital Symbol and
Block Design tests.
Stein et al., 2010 [46] 144 Subjects Participants with apolipoprotein 4 allele and lower
number of teeth had lower scores of Delayed Word
Recall at first examination and declined at a higher
rate compared to those without the presence of these
two risk factors.
Kaye et al., 2010 [47] 597 Subjects Each tooth loss per decade was linked to greater decline
of the Mini-Mental State Examination score and
spatial copying score.
Sparks Stein et al., 2012 [48] 158 Subjects Baseline serum antibody levels to Fusobacterium
nucleatum and Prevotella intermedia were
significantly increased in patients who later developed
AD compared to those who remained controls.
Kim et al., 2007 [49] 686 Subjects Significant connection was found between having fewer
teeth and dementia and AD in a 2,4-year follow-up.
Arrivé et al., 2012 [50] 405 Subjects People with 11 or more missing teeth and higher
education had a higher risk of dementia.
Okamoto et al., 2015 [51] 2,335 Subjects The risk of developing mild memory impairment is
increased by each tooth lost.
CP, chronic periodontitis; AD, Alzheimer’s disease; PD, periodontitis; PI, periodontal inflammation.
was significantly associated to increased risk for AD287
(hazard ratio (HR):1.08) and other forms of demen-288
tia (HR: 1.24 for vascular dementia and 1.16 for289
mixed dementia) [43]. A report on the analysis of the290
Korean Longitudinal Study on Cognitive Aging and291
Dementia (KLOSCAD) included 441 participants292
and demonstrated that higher number of functional293
teeth and functional occlusal units were associated294
with lower odds ratio (OR) of cognitive impairment295
(OR: 0.955 and 0.9, respectively) [44]. A Danish296
report analyzing 70-year-old individuals found that297
subjects with periodontal inflammation, with lower298
number of teeth have lower mean of Digit Symbol299
and Block Design score [45].300
Six prospective studies are available. A report of301
Stein et al., analyzing the results of Nun study involv-302
ing 144 individuals, demonstrated that lower number303
of teeth (range 1–9) associate with faster decline in304
cognitive scores measured with Delayed Word Recall305
test [46]. The Veteran Affairs Dental Longitudinal 306
Study followed 597 participants during 32 years with 307
a regular, 3-yearly repeated dental examination. Each 308
tooth loss per decade was associated with increased 309
decline in Mini-Mental State Examination Score 310
(HR: 1.09). Alveolar bone loss (HR: 1.03) and prob- 311
ing pocket depth (HR: 1.04) had an accelerating effect 312
as well [47]. A serum antibody experiment using the 313
Biologically Resilient Adults in Neurological Stud- 314
ies database examined 158 participants. 81 developed 315
dementia and 77 remained cognitively intact in the 316
years of follow-up. Baseline antibody level against 317
Fusobacterium nucleatum and Prevotella interme- 318
dia was significantly increased among individuals 319
developing dementia [48]. A cross-sectional analy- 320
sis nested within a study community dwelling elderly 321
resident in South Korea revealed that fewer number 322
of teeth was significantly connected to higher risk 323
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French observation in the region of Gironde follow-325
ing elderly at the age of 66–80 in a 15-year long326
period demonstrated 1.13 adjusted HR for number327
of missing teeth > 11 [50]. A study of Okamoto et al.328
examined 2,335 cognitively intact individuals in a 5-329
year long prospective setup and found 1.02 OR for330
mild memory impairment per 1 tooth loss at baseline331
[51]332
While there is a clear need for further longitudinal333
follow-up studies on patients with dental diseases,334
the above studies already indicate that dental disor-335
ders might contribute to the development of cognitive336
decline. Unfortunately, studies with meta-analysis on337
the risk of cognitive impairment among patients with338
PD are not available. Since PD affects an estimated339
11.2% of the world’s population [52], individual340
effect of PD should be analyzed in longitudinal stud-341
ies.342
THE POTENTIAL LINK BETWEEN ORAL343
DISEASES AND NEURODEGENERATION344
There are a few explanations that connect a chronic345
peripheral inflammatory disease to degeneration of346
the neural system, but two have been placed as the347
central pillars of the neuroinflammatory hypothesis348
connected to oral microbiome. These are (1) local349
invasion of pathogens in the central nervous system350
(CNS), and (2) bacteria related effect of inflammatory351
proteins and activated microglia inducing amyloid352
cascade.353
Local invasion of pathogens354
In 1884, Robert Koch formulated the famous355
Koch’s postulates [53], which allowed microbiol-356
ogists ever since to produce absolute proof that a357
specific microorganism causes a specific disease,358
revolutionizing the field of microbiology. However,359
with our advancing knowledge of human pathology,360
especially multifactorial diseases, we now know that361
Koch’s postulates do not hold for chronic diseases362
of possible microbial etiology, or for those that are363
multifactorial in origin. When considering diseases364
that begin taking effect at advanced age, a pathogen365
acting earlier in life might cause its damage via a366
“hit-and-run” mechanism [54] or could eventually367
be present only at a low concentration beneath the368
threshold needed to identify the organism at all. In369
multifactorial diseases, the causative organism might370
be missing if the disease is caused by some other fac-371
tors [54]. Since AD is a multifactorial disease, it is372
intriguing to analyze the presence of specific bacteria 373
whit a potential biological background to participate 374
in the neurodegenerative process. 375
Two routes by which it might be possible for 376
pathogenic bacteria present in the oral cavity to enter 377
the CNS are thought to be the intravascular route and 378
via peripheral nerves. Evidence gathered for these 379
routes has been obtained from studies associating 380
each specific organism with AD and will be described 381
in further detail in the “High risk pathogens” sec- 382
tion of this paper. Bacteraemia of oral origin can 383
occur during many daily dental’s and nondental 384
manipulations, and when pathogenic members of the 385
microbiota are released from their microenvironment, 386
they can migrate through our systemic circulation 387
intracellularly. Under the intravascular route, we can 388
point at monocytes or macrophages for function- 389
ing as vehicles that transport the pathogens into the 390
CNS. Maclnyte et al. [55], showed that monocytes 391
infected with periodontal pathogens can stimulate 392
transendothelial entry of monocytes through human 393
brain endothelial cells, via upregulation of adhesion 394
molecules on both receptor and cell. When Chlamy- 395
dia pneumoniae infected a cell sample, researchers 396
witnessed an increase in expression of adhesion 397
molecules such as ICAM-1 and VCAM-1, and sim- 398
ilarly bacterial colonization of monocytes increased 399
integrin (LFA-1 and MAC-1) expression. With these 400
two key components increased because of alerted 401
molecular expression, a 3-fold rise in migration of 402
monocytes was detected through this blood-brain bar- 403
rier model. Data collected in a study on the topic 404
[56], suggested that a compensatory response was 405
observed to maintain barrier integrity at the adherent 406
junction, where downregulation of junctional pro- 407
teins increased permeability. A 72-hour measurement 408
of these proteins was done [56] and found that perme- 409
ability changes were transient. These finding suggest 410
that an increased chance of transmigration of mono- 411
cytes through blood-brain barrier, could be the cause 412
of neurodegeneration. 413
The entry of pathogens to the CNS via the periph- 414
eral nerve route has been illustrated in Riviere’s 415
studies that showed that certain spirochete species 416
were detected in the trigeminal ganglia and pons, 417
highlighting the ability of oral bacteria to invade 418
CNS via peripheral nerves [57]. This suggestion is 419
supported by finding oral treponemas in the trigem- 420
inal ganglia in both AD and control patients [58, 421
59]. Treponemas were found to be concentrated in 422
foci and their histological location was identified by 423
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Fig. 1. The intravascular route for bacterial invasion of central nervous system. A) Periodontal bacteria are able to invade alveolar capillaries
and monocytes serve as transportation vehicles between alveolar and cerebral arteries. B) Infected monocytes could overexpress adhesion
molecules like ICAM resulting in accelerated transendothelial entry of periodontal bacteria to neural tissue through blood-brain barrier.
not be determined, a suggestion has been laid forth425
that Treponema originating from the oral cavity can426
invade both peripheral nervous system and CNS [58].427
Another study supporting this hypothesis was inves-428
tigating the immune infiltrates in the brain induced429
by peripheral stimulation. This was done by inject-430
ing L. monocytogenes into the oral mucosa of mice431
and goat. After just 6 days, 47/65 (72%) of mice432
developed signs of CNS inflammation. Further inves-433
tigation found mononuclear infiltrations all along the434
entire trigeminal nerve from the lips to the medulla435
[60].436
Once in the brain, periodontal bacteria that are rich437
in lipopolysaccharides (LPS) are capable of stimu-438
lating cytokine production and further potentiating439
AD neuropathology mechanisms, such as priming440
of microglia in response to amyloid- (A), dys-441
regulation of amyloid- protein precursor (APP)442
and A and initiating a neurotoxic loop [61] that443
changes from physiological to pathological when444
the intended neuroprotective functions of glial cells445
contribute to exacerbation of AD pathology. The446
presence of primed (activated) microglia can be447
attributed to either local or systemic inflammatory448
responses. These primed microglia are hypothe-449
sized to be a key part of AD neuropathology450
via inducing a higher production of inflammatory451
mediators and chronic overreaction to subsequent452
stimuli [62].453
Over prolonged periods of time, such as those dur-454
ing chronic PD infections, the presence of pathogenic455
bacteria in the CNS can increase the levels of inflam-456
matory products that may directly contribute to457
neurodegeneration via injury of surrounding nonin- 458
fected cells resulting in in neuronal loss [63]. 459
Inflammatory amyloid cascade and oral 460
pathogens 461
As suggested earlier, a second mechanism exists 462
through which periodontal pathogenic bacteria can 463
induce further neurodegeneration and propagate AD 464
in the brain. This mechanism does not include inva- 465
sion of pathogens into the CNS directly, but the same 466
effect is achieved through a PD derived increase of 467
inflammatory molecules in the brain. 468
Cytokines are known to play a key role in any 469
inflammatory response, and this is true for the neu- 470
roinflammation involved in modulating CNS function 471
in AD pathology. These cytokines are relatively 472
large hydrophilic molecules that cannot cross the 473
blood–brain barrier directly and as such their action 474
on the brain cannot be direct but requires intermedi- 475
ate molecules. The way these cytokines affect brain 476
function has been studied intensively over the past 477
decade. Activation of vagal afferents by cytokines 478
offers a rapid signaling mechanism into the CNS, 479
and this suggestion has been moved to the front of 480
the possible mechanisms list with studies done on 481
c-fos expression and vagotomy experiments [64]. 482
When considering cytokine-induced hypothalamic- 483
pituitary-adrenal axis activation, peripheral cytokines 484
have been proposed to activate the nucleus of soli- 485
tary tract via vagal afferents, this message continuing 486
to the paraventricular nucleus of the hypothalamus 487
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Fig. 2. Peripheral neural route for bacterial invasion of central nervous system. A) Red complex bacteria of periodontal plaques invade axon
terminals. Alveolar tissue is highly innervated by sensory branches of trigeminal nerve. B) Fibers of trigeminal nerve terminate in intracranial
ganglia providing an ideal environment for the survival of periodontal bacteria. Ganglionic axons could serve as a potential route toward the
brain stem nuclei for bacterial invasion.
totally exclusive neural transmission cannot account489
for the fact that elimination of brain cytokines repeals490
the key aspects of the acute phase response (such491
as behavioral depression or fever). It has therefore492
been proposed by Danzer et al. 2000 [64] that acti-493
vation of the vagal afferents by peripheral cytokines494
will induce a brain cytokine message that is respon-495
sible for the neuroinflammatory response. There is496
now sufficient evidence [64] to accept that cytokines497
can enter the brain from circumventricular organs498
(bypassing the blood-brain barrier) and the choroid499
plexus and propagate throughout the brain by extra-500
cellular diffusion to reach their target cells. It is501
now tempting to suggest that the humoral path-502
way is responsible for the passage of cytokines into503
the brain and the function of the neural pathway504
is to further sensitize and modulate target brain505
areas to increase or alter the effects of diffusing506
cytokines [64].507
The host response triggered by PD results in508
increased levels of inflammatory molecules such as509
TNF, IL1, IL6, IL8, and CRP. We will not go over510
the role of each specific chemokine in the inflam-511
matory amyloid cascade hypothesis of AD but refer512
readers to a great review on this topic that was513
published by [66]. However, it is worth mentioning514
that TNF- , IL-1, and IL-6 play a role in induc-515
ing cleavage of APP into A, and that the mere516
presence of A plaques increase the local concen-517
tration of these inflammatory cytokines, resulting in518
a feedback cascade that propagates AD. Since these519
cytokines may act on already primed glial cells result-520
ing in an amplified reaction, we can piece together521
the “Amyloid Cascade Hypothesis” with the “Neu- 522
roinflammatory Hypothesis”. A test of this combined 523
mechanism would require examination whether PD 524
affects the progression of AD regarding time or sever- 525
ity. According to the model proposed by Kamer et 526
al. [57], periodontal bacteria induce production of 527
pro-inflammatory cytokines and C-reactive protein 528
(CRP) which stimulate glial cells to produce A42 529
and hyperphosphorylated tau protein which results, in 530
further production of inflammatory molecules. Thus, 531
a vicious circle is established by the double role of 532
these cytokines in activating pathways leading to neu- 533
rodegeneration [57]. 534
Activated microglia (over)release many inflam- 535
matory mediators in the brain including cytokines, 536
prostaglandins, and acute phase proteins. The dysreg- 537
ulated handling and metabolism of A aggregates and 538
APP is of paramount importance in AD pathogen- 539
esis. A peripheral inflammation such as periodontitis 540
can increase cytokine production that alter the regu- 541
lation of APP and A. Griffin et al. [67] suggested 542
that IL-1 is critical to the processing of APP 543
and tilts the scale on the function of microglia to 544
ensure continued A deposition and the cyclical 545
continuation of inflammatory response and cytokine 546
overexpression [63]. The local CNS levels of IFN- 547
gamma and TNF are also increased during chronic 548
systemic inflammation or during bacterial coloniza- 549
tion of CNS tissue. These inflammatory mediators 550
also trigger A peptide production and alter the 551
metabolism of A and APP, in addition to inhibit- 552
ing soluble APP secretion [68]. Beta-secretase, 553
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Fig. 3. The systemic inflammatory mechanism of periodontal bacteria induced neurodegenerative process. A) Bacterial lipopolysaccharides
released from gingival plaques induce systemic immune response resulting in the elevation of numerous cytokines as IL-6 or IL-8. B)
Cytokines may leak into neural tissue in circumventricular organs, where blood-brain barrier is absent. Chronic neural presence of cytokines
could lead to a constant activation of microglia resulting in changes of amyloid clearance mechanism. Long-term stimulation of microglia
associates with increased formation of extracellular amyloid plaques. Parallelly, cytokine level increases in neural tissue due to the release
from microglia. The described process terminates in a vitious circle where cytokines stimulate microglia, and it releases more cytokines.
Overactivation of microglia results in increased amyloid burden and amyloid plaques serve as stimulator of microglial cells.
into its toxic A peptides, was shown to have555
its concentration increased by local inflammatory556
mediators [69].557
In the above-mentioned vicious cycle A aggre-558
gation further triggers the activation of microglial559
cells which in response produce acute-phase pro-560
teins, complement components, prostaglandins, and561
cytokines that further stimulate A production and562
aggregation. This response may be more injurious563
than the plaques and tangles to which inflamma-564
tory processes are responding, resulting in neural565
damage [63]. To further increase the devastating566
potential of this neurotoxic loop, other proinflam-567
matory cytokines such as IL-6 and TNF- can568
stimulate further A production, aggregation, and569
toxicity [63].570
HIGH RISK PATHOGENS571
An observational study conducted on patients with572
both active chronic PD and AD, suggested that after a573
6-month period, a significant decline in cognition was574
found among AD patients with periodontitis in com-575
parison to AD patients without active chronic PD,576
suggesting a link between neural degeneration and577
the presence of periodontal pathogens [14]. When578
attempting to correlating AD with PD, we should579
try to pinpoint the specific bacteria that provide a580
connecting link. In a consensus report written in581
1996, P. gingivalis, A. actinomycetemcomitans, and 582
T. forsythia were reported to be the three critical 583
periodontal pathogens [70]. A study was even con- 584
ducted in 2009 suggesting elevated levels of TNF 585
and antibodies against these three bacteria were 586
found in patients with AD (72% of AD subjects 587
were found with at least 1 antibody compared to 588
38% of control) [71]. Another study claimed PD to 589
be a polybacterial consortium focusing on P. gin- 590
givalis, T. denticola, and T. forsythia [72], and a 591
claim for correlation between these “red complex 592
pathogens” to AD was strengthened through many 593
studies conducted in the past decades observing more 594
oral pathogens (or inflammatory signals that medi- 595
ate oral-inflammation) in AD patients’ CNS [70–72]. 596
Since the above mentioned four bacteria form the “red 597
complex” pathogens of PD, we highlight studies on 598
these in relation to AD. 599
Spirochetes (Treponemas) 600
Spirochetes are well-known and defined periodon- 601
tal pathogens with 60 different species of Treponema 602
observed in subgingival pockets of patients with 603
diagnosed periodontitis [73]. We can estimate that 604
spirochetes account for 10% of the bacterial diversity 605
found in host tissue in a periodontal environment, and 606
when accounting for inflamed pockets, Spirochetes as 607













10 T. Werber et al. / The Link of Periodontitis and Alzheimer’s Disease
changes between individuals, where characteristics609
such as socio-economical background or even host610
genetics have a key role in the precise composition611
of the microbiome [75].612
PCR analysis of 16 AD brains found six different613
periodontal Treponemas (T. denticola, T. pectinovo-614
rum, T. vincenti, T. amylovorum, T. maltophilum, T.615
medium, and T. socranskii) in 14 of the studied brain,616
while only 4/18 of controls [58]. T. denticola and T.617
vincenti were found in a statistically significant por-618
tion of PD patients as opposed to normal subjects [76,619
77]. In addition, newly observed spirochetes were620
also found in these samples (T. pecitonovorum and621
T. socranskii) [74]. It is important to note that when622
assessing what subtype of spirochete would be a key623
component in the PD and AD link, we must consider624
a possibility of coinfection of multiple treponemas,625
and that they exhibit frequent pleomorphism in host626
tissue [58, 78].627
The effects of Treponemal spirochetes on human628
brains have been investigated for a while (the first629
paper was published in 1913), with Treponema pal-630
lidum in its atrophic form suggested to be a major631
cause for slowly progressive dementia, cortical atro-632
phy, and even local amyloidosis in the brain of general633
paralysis cases [79]. In another study, 60 patients with634
atrophic general paresis were analyzed and a correla-635
tion was found between an increase in spirochetes and636
spirochetal plaques (mostly hippocampal and frontal637
cortex), and the severity of cortical atrophy [80]. Tre-638
ponema infections can increase TNF productions by639
macrophages, with spirochetal lipoproteins having640
a key role in both local and systemic inflammation641
induced by the bacteria. In such treponema medi-642
ated inflammations, CRP and serum amyloid A levels643
were elevated [81], with increased CRP being corre-644
lated statistically to AD and dementia in a 25 year645
follow up study [82].646
To establish a bacterial link between PD and AD,647
evidence must be found of periodontal pathogens in648
confirmed AD patients. In a meta-analysis, in 91.1%649
(451/495) of AD patients were positive for Spirochete650
markers, while all 185 control samples were nega-651
tive [73]. A strong statistical correlation was shown652
between AD and oral Treponemas, not o ly because653
there was a much higher prevalence of Treponema654
DNA found in the brains of AD patients than con-655
trols, but there was also a much more diverse range656
of Treponemal species [60]. While Spirochetes offer a657
possible bacterial link between low grade oral inflam-658
matory disease and AD, more research is needed to659
finalize a conclusion.
Porphyromonas gingivalis 660
Periodontal tissue is known to exhibit a wide range 661
of bacterial species. Strong evidence has accumulated 662
to suggest that P. gingivalis is a key player in PD. P. 663
gingivalis can be found with greater frequency and 664
at elevated levels in diseased sites [83–86]. In one 665
study, 301 patients were examined, and a significant 666
correlation was shown between the prevalence of P. 667
gingivalis and periodontitis. Among PD patients 79% 668
(103/130) tested positive for the pathogen, in con- 669
trast to 25% (46/181) positivity of healthy patients 670
[87]. Statistical analysis suggested that the odds ratio 671
for being infected with P. gingivalis was 11.2 times 672
greater in patients with periodontitis than the control 673
group. 674
P. gingivalis is known to be a very resilient 675
pathogen, which might explain why even a low 676
amount in the brain for a duration of over 3 decades 677
could be enough to contribute to local inflammation 678
[88]. Two key molecules that are essential for the sur- 679
vival of P. gingivalis and its pathogenicity are Kgp 680
and RgpA/B. They are known to play a critical role 681
in the inactivation of host defense, nutrient acqui- 682
sition, and host colonization. In a study published 683
in 2019, 53 middle temporal gyri samples from AD 684
brains were analyzed and 51 (96%) tested positive for 685
RgpB and 49 (91%) for Kgp [89]. 686
In a study conducted to examine the possible rela- 687
tion between P. gingivalis and AD, in mice infected 688
with oral P. gingivalis the production of A plaques 689
was increased and colonization of the bacteria in the 690
brain could be spotted [90]. Another study found that 691
in 4/10 AD postmortem brain sections labelled with 692
mouse anti-P. gingivalis, strong cellular attachment 693
to the surface membrane was observed, as opposed 694
to none in the normal brains. This might be consid- 695
ered a cause of AD patients having an increased risk 696
of secondary chronic infection with P. gingivalis [91]. 697
LPS from P. gingivalis had been shown in AD 698
brains but not in non-AD brains [91]. It has been sug- 699
gested that P. gingivalis and gingipains (trypsin-like 700
cysteine proteinases) play a key role in the pathogene- 701
sis of AD by demonstrating their presence in rat brain 702
[79] and showing that in vivo gingipain inhibitors 703
block gingipain-induced neural decline, as well as 704
significantly reduce host A1–42 response to P. gin- 705
givalis and decrease the bacterial load in the mouse 706
brain [90]. 707
In one study [92] finalized in 2019, 20 AD patients 708
were examined for mental status and oral microbiota. 709
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P. gingivalis and a lower score on the Mini-Mental711
State Examination (MMSE) was found [92]. To fur-712
ther strengthen the claim that P. gingivalis is a key713
mediator between PD and AD, a periodontal infec-714
tion model in an ApoE4 -/- mice was used [93] and715
it was shown that P. gingivalis is more efficient and716




In 1996 a consensus report [70] set out to determine721
which are the core periodontal pathogens, and two of722
the bacteria named in this report due to their common723
occurrence in PD patients were T. forysthia and A.724
actinomycetemcomitans.725
Fast forward to the year 2019, and a group726
of Korean researchers have suggested the exact727
molecular mechanism through which Actinomycete-728
comitans causes its neuroinflammatory effects [94].729
Injection of this pathogens outer membrane vesicle730
was shown to increase expression of TNF- in mouse731
brain [94]. The correlation between AD and TNF-732
levels was established a decade earlier when Kamer733
et al. [71], showed that AD patients have elevated734
levels of this inflammatory marker. The alteration735
in host gene regulation (mainly via microRNAs that736
originate from the outer membrane vesicle of the737
pathogen) in response to the presence of A. actino-738
mycetecomitans indicates a possible pathway of how739
a pathogen specific systemic inflammation would740
increase the burden of neuroinflammation [94].741
The function of cytokines and chemokines in AD742
has been listed in the work of Lee et al. [95]. If our743
goal is to connect the neurodegenerative effect of744
these cytokines to the increased presence of them in745
response to a systemic bacterial assault, we need to746
find a potential increase of inflammatory markers in747
response to Periodontal pathogens. One study from748
2015 showed that A. actinomycetecomitans causes749
severe cytokine release in macrophages and induces750
cell death [96]. The mechanism for this was proposed751
to be via activation of NLRP3, an inflammasome752
prone to activation from microbial stimulus. NLRP3753
was also shown to play a role in the alteration of754
macrophage phenotype and influence A deposition,755
both pathognomonic for AD [97]. As a conclusion756
to the finding of the inflammasomes role in neu-757
ral decline, the Actinomycetecomitans – caspase 1-758
NLRP3 axis was suggested to represent a possible759
novel therapeutic option for AD [97].760
Aside from inflammatory markers, antibody levels 761
can also be used to assess the effect of pathogens on 762
the neural decline seen in AD (or MCI) patients. One 763
study [98] focusing on a group of bacteria (including 764
A. actinomyetecomitans) showed that antibody levels 765
of AD patients at baseline were matching the levels 766
found in chronic periodontitis patients. This demon- 767
strated that, possibly, elevated antibodies levels years 768
before cognitive decline could be a potential marker 769
for AD [98]. 770
Dı́az-Zúñiga et al. [98], were studying the serotype 771
of A. actinomyetecomitans that has the strongest 772
effect on the CNS. This is especially important 773
since the same report [70] that stated that A. acti- 774
nomyetecomitans is widespread in most PD patients, 775
also claimed that some types of A. actinomycetem- 776
comitans have a closer relationship with destructive 777
periodontal disease than other clonal types. Serotype 778
B was found to be that one that induces the largest 779
inflammatory response in microglia or hippocam- 780
pal cell cultures [98]. Actinomyetecomitans serotype 781
B LPS was shown to induce neural shrinking and 782
increase extracellular A1–42 formation, both char- 783
acteristics of AD. 784
It is commonly accepted today T. forsythia con- 785
stitutes a part of the “red complex pathogens” that 786
form the most pathogenic bacterial complex in the 787
oral cavity [72, 99]. When quantifying these bacteria, 788
a group of researchers studied 40 patients [100] with 789
confirmed PD and found that T. forsythia was found 790
in high amounts (60%) in the PD group compared 791
to healthy controls. When subtyping periodontitis to 792
different clinical groups, T. forsythia was found to be 793
4-fold higher in chronic periodontitis (the subtype of 794
PD most relevant to the link between systemic inflam- 795
matory and neural degeneration) than in aggressive 796
PD [100]. This chronic inflammatory response to the 797
presence of T. forsythia is hypothesized to play a role 798
in the propagation of AD [101]. 799
CONCERNS ON THE ROLE OF PD IN 800
COGNITIVE DECLINE 801
AD is a multifactorial disease where proba- 802
bly numerous physical conditions contribute to the 803
pathogenesis [7–13]. Plenty of scientific studies 804
linked cardiovascular diseases, metabolic disorders, 805
depression, sleep problems, or epilepsy to the neu- 806
rodegenerative process; however, the causative role 807
is frequently questionable and the “which comes 808
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important limiting factor for causability studies that810
there are plenty of overlaps between the described811
conditions and neurocognitive disorders. They fre-812
quently share similar genetic background: apo4 and813
MTFR are crucial genes in AD and cardiovascular814
diseases [104]; CALHM1 gene associates with higher815
excitability of hippocampal neurons and it is a genetic816
risk factor of AD [105]; 13 from 31 typical genes of817
major depression alternate with the known genes of818
AD [106]. Overlap could be demonstrated in the risk819
studies as well: hypertension is a well-known risk820
factor of heart attack and dementia according to the821
Framingham study [107] and CAIDE score studies822
[108]; while obesity associates with poor sleep qual-823
ity and insomnia [109], it is a common risk factor of824
AD [110]. Furthermore, the common shared etiology825
is represented well the by the socioeconomic status of826
patients with the various proposed conditions. Peo-827
ple with higher education and better financial and828
social background follow a healthier lifestyle and a829
more advanced self-attention including better nutri-830
tional quality (organic foods, low intake of omega-6831
and simple sugars, higher vitamin intake), regular832
physical exercise regime, less amount of stress, better833
access to adequate medical examination and screen-834
ing methods and they have more time to engage with835
various types of social activities to maintain and fuel836
cognitive functions. These people have lower chance837
for developing dementia and parallelly, they are more838
protected against cardiovascular or metabolic condi-839
tions [111].840
Since there is a great overlap between the genetic841
background, risk profile and socioeconomic status842
of patients with dementia and with physical dis-843
eases, it is intriguing to postulate that the association844
between the described medical conditions and AD845
is only an epiphenomenon. However, not all the846
patients with midlife depression or severe cardiovas-847
cular diseases develop dementia [112]. Furthermore,848
patients with AD show highly variable risk profiles849
[113]. These observations suggests that the men-850
tioned physical conditions might have a substantial851
or mild role in the neurodegeneration. A cording852
to the current scientific view, the mild synergistic853
role is the most acceptable [104]. It is also known854
as bidirectional relationship: while physical condi-855
tions can change the cleavage and elimination of856
toxic brain products, neurodegeneration associate857
with the destruction of functionally important brain858
areas resulting in the dysregulation of physiological859
processes (e.g., autonomic blood pressure regulation,860
sleep homeostasis, mood regulator neurotransmit-861
ter systems, hormone system). For instance, patients 862
with AD suffer from various sleep disorders, seem- 863
ingly patients with midlife insomnia show higher risk 864
for dementia [114]. 865
Similar questions are could be raised based on 866
the previously reviewed studies on the association 867
of PD and AD. They share common genetic pro- 868
files (e.g., polymorphisms of IL-6 and IL-10 genes 869
are risk factors for both conditions) [115], simi- 870
lar risk factors are detected (e.g., obesity, aging, 871
smoking) [1, 15] and poor socioeconomic status asso- 872
ciate with higher prevalence of PD [116] and AD 873
[117]. Studies analyzing AD patients regarding the 874
prevalence of PD (Table 1) are not able to properly 875
address the conceptualized concerns, since patients 876
with AD probably dedicate less attention to oral 877
hygiene and suffer from many comorbid physical 878
conditions. Prospective cross-sectional studies ana- 879
lyzing the long-term cognitive profile of PD patients 880
(Table 2) are better candidates; unfortunately, risk 881
profiles and socioeconomic status of these patients 882
were not reported. While currently the exact role 883
of PD in cognitive decline is not addressable, some 884
reports suggest plausible association. Since not all 885
PD patients develop AD and there are great variabil- 886
ities among PD patients regarding the risk factors 887
and extent of dental inflammation [118], causative 888
relationship might be hypothesized. Bases on the 889
observations showing colonization of brain tissues 890
with common PD pathogens, bidirectional, mild 891
synergistic effect of PD seems to be feasible in 892
the development of cognitive decline [119]. Likely, 893
presence of PD could exaggerate other pathologic 894
processes via the neuroinflammatory mechanisms 895
resulting in various types of neuropsychiatric dis- 896
orders (e.g., migraine, major depression, multiple 897
sclerosis) [120], not AD only. To properly address the 898
direction of causative role in cognitive impairment, 899
unified reporting is mandatory for PD studies to gen- 900
erate numeric databanks for large sample statistical 901
analyses. 902
CLINICAL RECOMMENDATIONS FOR 903
PROSPECTIVE RISK ANALYSIS AND 904
INTERVENTIONAL STUDIES 905
Although numerous reports link PD to cognitive 906
impairment, no prospective PD intervention stud- 907
ies have evaluated dementia outcomes. A search for 908
“Periodontitis” and “Alzheimer” and “Treatment” 909
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Human studies or randomized clinical trials on the911
treatment of PD in the prevention of dementia are912
absent. However, based on prevalence studies and913
the inflammatory effect of PD, it seems reasonable914
to postulate that PD might represent an individual915
risk factor for the development of cognitive decline.916
Thus, we propose a clinical recommendation guide917
for further PD interventional trials in the prevention918
of dementia.919
Patients with risk of dementia without a previous920
diagnosis of periodontitis921
Recognition of high-risk patients922
Recognition of high-risk individuals for further923
development of cognitive impairment is manda-924
tory for modern health systems. Individuals without925
subjective decline on cognitive functions might926
represent a risk group for AD in the follow-927
ing cases: age > 65, family history of dementia,928
education years < 10, APOE4 carriers, smokers, diag-929
nosis of atherosclerosis, hypertension, high level of930
low-density lipoprotein (LDL), high level of homo-931
cysteine, diagnosis of diabetes, midlife obesity [121].932
Patients with a diagnosis of MCI have significantly933
elevated risk compared to previous subjects [122].934
Patient information935
Dental and medical professionals should strongly936
cooperate to increase compliance of patients and937
effectivity of potential dental care. Patients with a938
risk of dementia should be informed that poor den-939
tal health associates with increased risk for cognitive940
impairment. Importance of proper oral hygiene must941
be emphasized in all medical check-ups. Patients with942
known risk factors of dementia should consider a den-943
tal evaluation if they have not done so in the past 12944
months (it is illustrated by a key point taken from the945
world cohort study [123] that the risk for developing946
dementia was 89% greater in those who had not seen947
their dentist within the last 12 months compared to948
those who had seen their dentist two or more times).949
Patients should be informed that PD is often asymp-950
tomatic and does not associate with systemic signs951
of infections (e.g., fever, flu like symptoms) or with952
prominent changes of blood test values (e.g., leuko-953
cytosis, significantly increased CRP). Patients should954
be also educated about the common physical signs of955
PD as swollen gums, bleeding gums (spontaneously956
or following brushing or flossing), pus between teeth957
and gums, increased space between teeth and gums,958
sensation of bad taste or bad oral odor, change in959
tooth sensation during biting, spontaneous oral pain 960
or mastication associated oral pain. 961
Dental evaluation 962
Periodontal evaluation of patients with high 963
dementia risk should include a comprehensive exam- 964
ination of periodontal tissues. Dental medical history 965
should be updated. Presence of diseases associat- 966
ing to higher occurrence of PD (Chediak-Higashi 967
syndrome, agranulocytosis, leukocyte adhesion defi- 968
ciency, Down syndrome, Papillon Lefevre syndrome, 969
cyclin neutropenia) needs special attention in dental 970
records [124]. Plaque and bleeding on probing (BoP) 971
should be assessed by trained examiners, probing 972
depths, and clinical attachment level (CAL) should be 973
recorded and both full-mouth and site-specific stabil- 974
ity should be determined. Radiography (dental status 975
x-ray) should be applied in all suspicious cases to 976
detect potential bone loss. Oral hygiene instruction 977
regarding appropriate frequency, technique and use 978
of potential aids such as interdental brushes should 979
be tailored to patients’ needs individually. 980
Intervention procedures should be performed to 981
prevent biofilm formation, which is the major cause 982
of chronic PD. This is best achieved by replac- 983
ing insufficient restorations having leakage and/or 984
overhangs, thereby creating cleansable surfaces. 985
Reducing plaque retention can be reached by restor- 986
ing natural tooth contour and contact points with the 987
necessary restorations. Once the pro-plaque accu- 988
mulating factors are eliminated regular professional 989
dental hygiene treatment can help in maintaining the 990
oral health at an acceptable level without having acute 991
and chronic inflammation. 992
Risk control 993
Risk profile of PD should be recorded by medi- 994
cal and dental check ups yearly. The following risk 995
factors must be included: smoking, diabetes, family 996
history of PD, obesity, depression, physical inactiv- 997
ity. Evaluation might be performed in a cooperation 998
with dementia care professionals using standardized 999
diagnostic tools for mood (e.g., Geriatric Depres- 1000
sion Scale, Beck Depression Inventory, Hamilton 1001
Rating Scale for Depression) and physical inactivity 1002
(e.g., International Physical Inactivity Questionnaire, 1003
Global Physical Activity Questionnaire). Patients 1004
with a risk factor should be informed that they might 1005
have elevated risk for the development of PD. 1006
All patients should be informed about the poten- 1007
tial lifestyle intervention possibilities to prevent PD. 1008
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should discontinue this habit. Diabetes should be1010
strictly monitored with regular blood testing (blood1011
sugar level, Hemoglobin A1C) and properly con-1012
trolled by a health professional trained in diabetes.1013
Antidiabetic drugs having a potential beneficial effect1014
in the prevention of cognitive impairment (intranasal1015
insulin, metformin, GLP-1 agonist) should be priori-1016
tized [125]. Lifestyle interventions should be initiated1017
in patients with obesity and physical inactivity. The1018
nutritional intervention could be based on the Finnish1019
Nutrition Recommendations since beneficial effect1020
has been proved by many prospective interventional1021
trials [126–127]. The exact nutrition protocol is char-1022
acterized in the study of Souminen et al. [128].1023
Mediterranean diet or Dietary Approach to Systolic1024
Hypertension could represent reasonable choices as1025
well [129]. Intervention plan for physical exercise1026
protocol could be based on the 2007 ACSM/AHA1027
recommendations. The exact strategy is described in1028
the paper of Nelson et al. [130]. Patients with low1029
mood should be referred to trained psychologists1030
or psychiatrists having experience in the preven-1031
tion of cognitive decline. Behavioral therapy should1032
be prioritized, and antidepressants might have neg-1033
ative adverse effects due to the increase of vascular1034
events [131]. If antidepressant therapy is mandatory,1035
citalopram might represent a reasonable choice since1036
anti-amyloid effect has been proved in clinical tri-1037
als [132]. However, long-term treatment beyond 121038
weeks with antidepressants is not advised [133].1039
Patients with risk of dementia and a diagnosis of1040
periodontitis1041
Patient information1042
Patients with newly diagnosed PD should be1043
informed that there may be an increased risk for1044
AD dementia. Patients should be informed that treat-1045
ment for PD is available, and inflammation might be1046
reduced but not completely cured. A plan to reduce1047
the effect of possible contributors of PD (smok-1048
ing, diabetes, obesity, low mood, physical inactivity)1049
should be advised, as we have demonstrated in the1050
“Risk control” section.1051
Classification and reporting of PD parameters1052
A consensus on the definition of periodontitis case1053
is crucial. We propose to use the current consensus1054
statement of the 2017 World Workshop on the Clas-1055
sification of Periodontal and Peri-Implant Diseases1056
and Conditions [16]. PD could be identified in the fol-1057
lowing case: 1) interdental CAL is detectable at ≥ 21058
non-adjacent teeth, or 2) Buccal or oral CAL ≥ 3 mm 1059
with pocketing > 3 mm is detectable at ≥ 2 teeth. Fur- 1060
ther important criteria for case definition are that the 1061
assessed CAL is not associated with non-periodontal 1062
causes (gingival recession of traumatic origin, cervi- 1063
cal dental caries, CAL on the distal surface of second 1064
molar associating with malposition or extraction 1065
of third molar, endodontic lesion draining through 1066
marginal periodontium, vertical root fracture). We 1067
propose to report if periodontitis occurs in a necrotiz- 1068
ing form or associate with severe systemic diseases. 1069
For risk analysis, description of PD status with 1070
a unified staging form is mandatory to estimate 1071
the contribution of periodontal disease in cognitive 1072
impairment. We propose to use a system based on the 1073
current staging protocol of the 2017 World Workshop 1074
on the Classification of Periodontal and Peri-Implant 1075
Diseases and Conditions (see Table 3). Our proposed 1076
score could be applied during dental visits, since 1077
the system includes easily administrable parameters 1078
measuring general PD risk as well. The major aim of 1079
the staging system is to estimate the severity of PD 1080
with measurable dental parameters and highlight par- 1081
allelly the potential contributors of PD. The reporting 1082
protocol is based on the current recommendations 1083
of PD care and on the previously reported param- 1084
eters of case-control and cross-sectional studies on 1085
the association of PD and AD. 1086
Dental treatment 1087
The aim of treatment of PD is to reach a stable, 1088
inflammation free stage of periodontium (supportive 1089
structures of teeth) to provide ability for proper tissue 1090
regeneration. During the treatment procedure called 1091
scaling, sites showing signs of stability or inflam- 1092
mation without disease progression must undergo 1093
supragingival removal. This can be done with a 1094
variety of tools and approaches. To minimize the 1095
number of bacterial deposits, the specific features 1096
that are likely to retain plaque and calculus should be 1097
eliminated. In addition, several additional measures 1098
are proposed to minimize plaque accumulation and 1099
inflammation, including additional antimicrobials 1100
and lasers. Indicators of active disease require retreat- 1101
ment including signs of inflammation (e.g., BoP) and 1102
an increase in CAL. Subgingival debridement is also 1103
recommended at sites greater than 4 mm regardless of 1104
signs of inflammation or recurrent disease, as the risk 1105
of relapse increases with deeper probing depth mea- 1106
surements. Periodontal healing occurred even in the 1107
presence of calculus, provided the subgingival bacte- 1108
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Table 3
Periodontitis reporting protocol for cognitive risk analysis studies and for prospective interventional trials. Severity could be reported with
clinical attachment level (CAL), radiographic bone loss (RBL), and with tooth loss (TL). Reporting of exact numbers for CAL, RBL, and
TL is advised to provide possibility for correlation analysis with cognitive and neuroimaging scores. Maximum probing depth should be
reported too since it is frequently used in previous risk and cohort studies. Extent and distribution of PD should be reported too to create
more numeric parameters for further statistical analysis. Type of periodontitis might distinguish various outcomes. Risk profile could be
easily administered and helps to identify the common contributors of periodontitis and cognitive decline
Periodontitis reporting protocol

















TL No tooth loss due to periodontitis Tooth loss due to
periodontitis
of ≤ 4 teeth
Tooth loss due to
periodontitis
of ≥ 5 teeth
Maximum probing depth Maximum probing depth ≤ 4 mm
Maximum probing depth ≤ 5 mm
Maximum probing depth ≥ 6 mm
Extent and distribution Localized (< 30% of teeth involved)
Generalized (> 30% of teeth involved)
Molar/incisor pattern
Type of periodontitis Chronic periodontitis
Necrotizing periodontitis
System disorder associated periodontitis (specify disease: . . . )
Risk profile Family history of periodontitis (yes/ no)
Smoking (yes, no/ cigarettes/day: . . . )
Diabetes (yes-no/ controlled-uncontrolled)
Obesity (yes, no/ BMI: . . . )
Physical inactivity (amount of moderate activity in minutes/week: . . . )
Mood disorder (yes/no/ controlled- uncontrolled)
although calculus removal is important because it is1110
a major plaque-retaining factor, intentional removal1111
of root material and contaminated cement is not1112
necessary for successful treatment. Thus, the term1113
root planing is often referred to today as debride-1114
ment. Most studies in the 1970s and 1980s were1115
conducted with hand tools, including curettes, scales,1116
and hoes, and this was considered the gold stan-1117
dard. Since the 1990s, the use of powered instruments1118
has become increasingly popular, claiming increased1119
efficiency and effectiveness. Adverse effects after1120
non-surgical removal may include patient discom-1121
fort, damage to the root surface, and sensitivity1122
of the root surface. Excessive removal should be1123
avoided at shallow probe depths (< 3 mm) to avoid1124
trauma, subsequent loss of binding, and root surface1125
sensitivity. In the treatment of deep pockets (prob-1126
ing depth > 6 mm), surgical procedures as open-wing1127
debridement, should be considered since they might1128
result in greater probe depth reduction and clinical1129
binding gains. Flap surgery might help in the cleaning1130
of vulnerable surfaces. With soft tissue graft tech-1131
niques, gum recession could be significantly reduced, 1132
and we are able to cover exposed routes. In alveo- 1133
lar tooth loss, bone grafting helps to prevent tooth 1134
loss and serves as a platform for renewal of nat- 1135
ural bone tissues. Guided tissue regeneration and 1136
tissue-stimulating proteins also support the regrowth 1137
of natural alveolar bone tissues. While there are vari- 1138
ety of possible treatment strategies, re-evaluation of 1139
PD stages with the proposed protocol is mandatory 1140
to accurately report therapeutic effect in prospec- 1141
tive interventional trials preferably in yearly basis. 1142
Changes in PD risk profile could be easily adminis- 1143
tered. 1144
DISCUSSION AND CONCLUSION 1145
AD is a devastating neurodegenerative disorder 1146
and the leading cause of cognitive impairment. 1147
Recent studies demonstrated that with early recog- 1148
nition and proper control of risk factors, we can 1149
significantly delay the occurrence of dementia or pre- 1150
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Table 4
Summary of strategies in the management of high-risk individuals for cognitive decline with and without periodontitis
Patient groups Patients without previous Patients with the
diagnosis of PD diagnosis of PD
Recognition of high-risk -age > 65
individuals for cognitive -family history of dementia
decline -education years (< 10)
-APOE4 status+
-smoking
-atherosclerosis (carotis or coronary stenosis/ white matter lesions on brain MRI)
-hypertension (blood pressure > 140/90
-high level of low-density lipoprotein (> 100 mg/dl)
-high level of homocysteine (> 15 mcmol/l)
-diagnosis of diabetes
-obesity (BMI > 25)
Patient information -dental evaluation once/12 months -elevated risk for AD
-risk of poor dental health regarding
cognitive decline
-importance of dental treatment and
check-ups
-proper oral hygiene techniques -importance of lifestyle interventions
-physical signs of PD
Dental evaluation -anamnesis: high risk diseases for PD -measuring of CAL, BoP, TL (mandatory)
-measuring of BoP and CAL (mandatory) -dental status x-ray and description of RBL
(mandatory)
-dental status x-ray (if necessary) -measuring of extension (mandatory)
-measuring of type of PD (mandatory)






-family history of PD
-obesity (BMI > 25)
-diagnosis of depression
-physical inactivity (< 4 × 30 min of exercise/week)




-behavioral or antidepressant therapy of mood disorders
PD, periodontitis; BMI, body mass index; AD, Alzheimer’s disease; CAL, clinical attachment level; BoP, bleeding on probing; TL, tooth
loss; RBL, radiographic bone loss.
the most frequent dental disease sharing many mod-1152
ifiable risk factors with AD.1153
Case-control studies revealed that PD has a higher1154
prevalence among AD patients. However, recent1155
meta-analyses propose that the exact role of PD1156
in dementia is barely measurable since they differ1157
significantly in the methodology, especially in the1158
reporting protocol of dental status [29]. While plenty1159
of prevalence studies use the periodontitis term [25,1160
36, 38], exact definition of periodontitis is rarely1161
described. Others analyze the occurrence of poor gen-1162
eral dental health among dementia patients [24, 34];1163
however, they also reveal periodontal parameters like1164
tooth loss or pocket depths. In case-control studies,1165
analysis of periodontal bacterial linked inflammatory1166
markers is also common [31–33, 35–36], but peri- 1167
odontal status is reported with various parameters 1168
or not reported at all. Matched-cohort and observa- 1169
tional retro- and prospective studies clearly suggest 1170
the role of PD in neurodegenerative disorders. Unfor- 1171
tunately, meta-analysis studies are not available, and 1172
comparison of results is complicated since reports use 1173
different parameters to report PD status. Exact defini- 1174
tion of PD is defined only in one of these studies [40], 1175
where severity or staging of PD is not reported. In 1176
many studies, diagnostic procedure to describe PD is 1177
not highlighted and PD severity is measured only with 1178
the number of teeth [43–47, 49–51]. Some studies 1179
measured serum antibody levels against PD bacteria 1180
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While there are large variety in reporting method-1182
ology by reports focusing on the link of AD and PD,1183
physiology studies have revealed potential mecha-1184
nisms for the periodontal bacterial contribution in1185
neurodegeneration. Seemingly, pathogens of peri-1186
odontal plaques can reach the neural tissue via1187
an intravascular route with monocytes [55] or via1188
the peripheral sensory alveolar branches of trigem-1189
inal nerve and its ganglia [58]. Systematic cytokine1190
response for periodontal bacteremia was highlighted1191
too [57], resulting in a vitious circle between cytokine1192
release, microglia activation, and amyloid formation1193
[68]. These possible mechanisms are reinforced by1194
human studies finding elevated level of antibodies and1195
cytokines against periodontal bacteria [31–33, 35–36,1196
41, 48] and by clinical reports showing elevated1197
occurrence of red complex pathogens of PD in human1198
brain tissues. Seemingly, four species have prioritized1199
role in PD-linked neurodegeneration: Spirochetes1200
[73], P. gingivalis [91], A. actinomycetans [98], and1201
T. forsythia [102]. Based on the previously described1202
observations, it is intriguing to plan further studies to1203
analyze the role of PD in cognitive impairment and1204
to measure the effect of PD treatment in interven-1205
tional trials of AD. However, unified clinical strategy1206
and reporting of PD status is mandatory to increase1207
comparability and reproducibility.1208
In the current review, we provide a strategy to1209
manage patients with elevated risk for dementia and1210
without PD. Education of patients about PD, risk1211
reduction and improvement of oral hygiene and pro-1212
motion of dental visits might be crucial to decrease1213
PD and dementia burden parallelly. Since risk fac-1214
tors of AD and PD highly overlap, these strategies1215
serve well the prevention of both diseases. In patients1216
with PD, uniformized reporting of dental and PD1217
status could be key for further cross-sectional risk1218
studies and interventional trials. We propose a PD1219
reporting protocol (Table 3) containing the follow-1220
ing features: 4-stage model for assessing severity1221
based on three clinical parameters (CAL, RBL, TL);1222
maximum probing depth to provide opportunity to1223
compare results to previous reports; description of1224
extent and PD type to reveal PD profile; and risk pro-1225
file administrable by dentists. The proposed protocol1226
is summarized in Table 4.1227
In conclusion, we can propose that PD might be1228
an important contributor of neurodegeneration. Fur-1229
ther studies are needed with prospective follow-up1230
to measure the impact of PD status on cognitive out-1231
come. Strict reporting of PD parameters is mandatory1232
to reveal exact effect of dental health and to make1233
comparison available with established biomarkers 1234
of neurodegeneration (e.g., cerebrospinal fluid, neu- 1235
roimaging, neuropsychology). Patients with high 1236
dementia risk might benefit from PD prevention and 1237
treatment strategies and these can be important con- 1238
tributors of prevention trials. 1239
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